==== Front J Fungi (Basel) J Fungi (Basel) jof Journal of Fungi 2309-608X MDPI 33228010 10.3390/jof6040300 jof-06-00300 Review Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going? do Carmo Silva Lívia 12*† de Oliveira Amanda Alves 12 https://orcid.org/0000-0003-1683-1514de Souza Dienny Rodrigues 12 Barbosa Katheryne Lohany Barros 12 https://orcid.org/0000-0001-5350-7313Freitas e Silva Kleber Santiago 1 https://orcid.org/0000-0003-1513-3247Carvalho Júnior Marcos Antonio Batista 1 https://orcid.org/0000-0002-2094-6042Rocha Olívia Basso 1 https://orcid.org/0000-0003-1210-8302Lima Raisa Melo 12 Santos Thaynara Gonzaga 12 https://orcid.org/0000-0001-5378-9840Soares Célia Maria de Almeida 1 Pereira Maristela 1*† 1 Laboratory of Molecular Biology, Institute of Biological Sciences, Federal University of Goiás, Goiânia 74690-900, GO, Brazil; o.amanda.alves@gmail.com (A.A.d.O.); diennybiotec@gmail.com (D.R.d.S.); katherynelohany@gmail.com (K.L.B.B.); smallbinho@hotmail.com (K.S.F.eS.); carvalhojr.biolic@gmail.com (M.A.B.C.J.); oliviabassorocha@gmail.com (O.B.R.); raisamelolima@hotmail.com (R.M.L.); thaynara075@hotmail.com (T.G.S.); cmasoares@gmail.com (C.M.d.A.S.) 2 Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, GO, Brazil * Correspondence: liviacarmo@ufg.br (L.d.C.S.); mani@ufg.br (M.P.); Tel./Fax: +55-62-3521-1110 (M.P.)† To whom correspondence and material requests should be addressed to Laboratory for Molecular Biology, Federal University of Goiás, Avenida Esperança, s/n, ICB2, Sala 206, Goiânia 74690-900, GO, Brazil. 19 11 2020 12 2020 6 4 30023 9 2020 16 11 2020 © 2020 by the authors.2020Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Paracoccidioidomycosis is a neglected disease that causes economic and social impacts, mainly affecting people of certain social segments, such as rural workers. The limitations of antifungals, such as toxicity, drug interactions, restricted routes of administration, and the reduced bioavailability in target tissues, have become evident in clinical settings. These factors, added to the fact that Paracoccidioidomycosis (PCM) therapy is a long process, lasting from months to years, emphasize the need for the research and development of new molecules. Researchers have concentrated efforts on the identification of new compounds using numerous tools and targeting important proteins from Paracoccidioides, with the emphasis on enzymatic pathways absent in humans. This review aims to discuss the aspects related to the identification of compounds, methodologies, and perspectives when proposing new antifungal agents against PCM. Paracoccidioidomycosisantifungalnanotechnologypatent ==== Body 1. Introduction The infection caused by fungi of the genus Paracoccidioides was first described by Adolpho Lutz in 1908. In 1971, during the meeting of several mycologists from Latin America in Medellín-Colombia, the term Paracoccidioidomycosis (PCM) was made official to designate the systemic granulomatous infection caused by the thermodimorphic fungi of the genus Paracoccidioides [1,2]. Several aspects of the infection remained unknown for a long period, including the taxonomic classification of the pathogen and a more appropriate therapeutic approach [3]. Nowadays, however, the importance of this disease in Latin America is recognized, with it being one of the main causes of deaths due to fungi infections [4]. The eradication of the fungus in the tissues is slow and treatment might last from months to years of antifungal administration. Paracoccidioides spp. are sensitive to various systemic antifungals, but the therapeutic options are limited to antifungals that act on two main targets, plasma membrane and folic acid synthesis [5]. Several new compounds with antifungal properties have been proposed against PCM over the last decade. Thus, this review focus on studies that have identified alternative compounds to the current treatment of PCM, as well as the strategies used for the development of new antifungal drugs. To review the antifungal compounds used in the treatment of PCM, a search was performed in SciELO (Scientific Electronic Library Online, https://scielo.org/), PubMed (https://pubmed.ncbi.nlm.nih.gov/), PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/), and Virtual Health Library (https://bvsalud.org/) databases in August 2020. We used the Medical Subject Headings (MeSH) terms “Paracoccidioidomycosis” OR “Infection, Paracoccidioides brasiliensis” OR “South American Blastomycosis” OR “Paracoccidioides brasiliensis Infection” OR “Paracoccidioides” OR “Paracoccidioides brasiliensis” AND “Antifungal” OR “Agents, Antifungal” OR “Fungicides, Therapeutic” OR “Antibiotics, Antifungal” OR “Antifungal Antibiotics” and for searches in Portuguese we use the Health Sciences Descriptors (DeCS) terms: “Blastomyces brasiliensis” OR “Paracoccidioides” OR “Paracoccidioidomicose” OR “Blastomicose Sul-Americana” OR “Granuloma Paracoccidioides” OR “Infecção por Blastomyces brasiliensis” OR “Infecção por Paracoccidioides brasiliensis” AND “Antifúngicos” OR “Agentes Antifúngicos” OR “Agentes Antimicóticos” OR “Antimicóticos” OR “Fungicidas Terapêuticos”. These results are presented in complementary tables consisting of antifungal derived from the synthetic and semi-synthetic compounds tested against Paracoccidioides spp. (Table S1), the antifungal compounds from plants and microorganisms’ sources tested against Paracoccidioides spp. (Table S2), and the nanoparticles of antifungal immobilized compounds tested against Paracoccidioides spp. (Table S3). 2. Treatment of Paracoccidioidomycosis: An Overview Figure 1 shows the historical context that defines the treatment of PCM currently. The first alternative treatment emerged in 1940, 32 years after the first reports of the disease by Lutz, using sulfapyridine, which is a sulfonamide derivative [6]. Sulfonamides are recognized for their broad spectrum of antibiotic activity, interrupting the growth of microorganisms by the competitive inhibition of the aminobenzoic acid (PABA) to the enzyme dihydropteroate synthase in the folate synthesis pathway. The latter is an essential component in the synthesis of nucleic acids and proteins [7,8]. Sulfa derivatives were also used in the treatment of PCM according to the severity of the disease, including compounds of low, moderate, and high excretion by the body [5]. Treatment with amphotericin B (AmB) was introduced by Lacaz and Sampaio [6] in 1958. This drug was established as an antifungal agent with a wide spectrum of action, acting mainly through the formation of complexes with ergosterol. These are molecules present in the membranes of fungal cells and responsible for the formation of transmembrane channels that allow the extravasation of cytoplasmic components [9]. It is indicated for severe and disseminated forms. Despite its effectiveness, AmB is also able to bind, to a lesser extent, to the cholesterol present in mammalian cells, producing several toxic effects on the host during the course of treatment, including acute symptoms such as nausea, vomiting, fever, hyper and hypotension, and hypoxia, in addition to chronic nephrotoxicity [10,11]. New formulations of AmB were developed for incorporation into liposomes, resulting in a better tissue distribution and less toxicity [5]. Another treatment option for PCM emerged with the introduction of cotrimoxazole (CMX) in 1973. This drug is a synergistic association between sulfamethoxazole (a sulfonamide derivative) and trimethoprim, and is used in patients with mild to moderate forms of PCM and neuroparacoccidioidomycosis [12,13,14]. CMX acts by inhibiting the enzymes involved in the synthesis of tetrahydrofolic acid, leading to the depletion of intracellular folate, which is essential for the growth of the pathogenic organism [15]. The development of azole derivatives certainly supported the expansion of the arsenal of antifungals against PCM. These compounds are the most common agents used in the treatment and prevention of a wide spectrum of mycoses, preventing the biosynthesis of ergosterol by inhibiting the CYP450-dependent enzyme, lanosterol 14-α-demethylase [16,17]. Two years after its publication in 1979, ketoconazole was introduced as an antifungal for the treatment of PCM [18,19,20]. Despite the success of this drug in controlling mild and moderate forms of the disease, its use is no longer recommended due to hepatotoxicity and adrenal insufficiency [21]. Thus, ketoconazole was eventually replaced by the first generation of triazoles, especially after the introduction of itraconazole (ITZ) in 1987 [22]. Some other alternative treatments have been proposed over the past two decades. A case report published in 2000 showed a patient who did not respond to the initial treatment with CMX but achieved clinical, mycological, and radiological cures two years after the end of treatment with terbinafine [23]. Terbinafine is an antifungal of the allylamine class that has a similar mechanism of action to azole agents, blocking the ergosterol biosynthesis pathway by inhibiting the squalene enzyme epoxidase [24]. A representative of the second-generation triazoles known as voriconazole has a similar efficacy to ITZ, and is useful in the treatment of neuro-PCM due to the greater penetration of this drug into the central nervous system compared to ITZ [25]. The publication of the consensus on PCM in 2006 allowed the creation of guidelines to formalize the PCM clinical treatment. Shikanai-Yasuda recommends the use of ITZ as the drug of choice for the treatment of mild and moderate forms of PCM, followed by CMX and AmB, according to the severity of the disease. The consensus also points to the possibility of using voriconazole, posaconazole, and isavuconazole to replace itraconazole, paying attention to costs, clinical evidence, and drug interactions [14]. Even after one hundred years of investigation into the disease, the therapeutic approaches face several issues. The main problem to overcome concerns the long period of treatment required by the currently available antifungals, which occasionally results in patients giving up therapy [26]. Another issue is the possibility of Paracoccidioides developing resistance against these antifungals. In Paracoccidioides spp., genes that were homologous to the cerebellar degeneration-related protein (CDR1, CDR2) and multi-drug resistance (MDR1) of Candida albicans, the pleiotropic drug resistance (PDR5) of Saccharomyces cerevisiae, and the ABC transporter genes of Aspergillus spp. were observed; all of them were related to resistance against azoles [27]. Thus, as the current treatment against PCM is mainly based on azole derivatives, these genes may play a similar role in Paracoccidioides spp., with the possibility of developing resistant isolates. In fact, the in vitro resistance of Paracoccidioides spp. was evidenced against azole derivatives [28]. Cermeño et al. carried out a sensitivity test of several species of Paracoccidioides spp. and observed the resistance against caspofungin (94.7%), followed by 5-flucytosine (52.6%) and AmB (47.4%) [29]. In addition to antifungal therapy, the treatment of possible sequelae of PCM such as pulmonary fibrosis and the prevention of opportunistic diseases should also be considered. An additional therapy proposal for PCM aimed at reducing pulmonary fibrosis is the combination of itraconazole-pentoxifylline. However, although the combination has shown promising results in mice, there are still no reports on testing in humans. 3. New Anti-Paracoccidioides Compounds: Do We Already Have Any Ideal Antifungals? The ideal antifungal agent should have a broad activity; be selective for fungal targets; and have reduced adverse effects, limited interactions, many administration routes, and low resistance. Thus, proteins belonging to the metabolic pathways involved in amino acid metabolism, cell wall, ergosterol biosynthesis, response to oxidative stress, and alternative sources of carbon are targets for antifungals and explored in the process of identifying new selective compounds. Such parameters are essential for the survival of the pathogen and additionally those targets should be absent in humans [30]. Over the years, several techniques and approaches helped to search for promising antifungals (Figure 2). The ability of a compound to inhibit fungal growth is known as Minimum Inhibitory Concentration (MIC). MIC was first used in a PCM study in 1982 to assess the in vitro effects of CMX against P. brasiliensis clinical isolates [31]. However, one of the major problems is the lack of standardization in these tests, which is directly related to the variety of MIC protocols found in the literature. Experimentally, tests that identify MIC values have been performed for several years through the macrodilution technique or by counting colony-forming units. This technique was improved by converting these assays to microdilution using 96-well microplates in 2003 [32]. In addition, the proposition of using resazurin dye as a marker of metabolic activity provided even greater practicality for those assays in 2013 [33]. Studies reported that certain variables, such as culture medium and incubation time, have a major impact on the results [34]. Although there is a trend towards the use of the RPMI-1640 culture medium, as recommended by the Clinical and Laboratory Standards Institute (CLSI) [35], the incubation time still remains undefined, ranging from 3 to 15 days of incubation [36,37]. The search for new antifungal candidates has been driven by synthetic, semi-synthetic, plant. and microorganism compounds. In this review, we describe some of the compounds tested against Paracoccidioides spp., and additional compounds are listed in Tables S1 and S2. Potential compounds act as growth inhibitors against Paracoccidioides spp. in low concentrations (Table S1), such as alkyl gallates (0.004–16 µg/mL), an N-Glycosylation inhibitor [38,39]; the thiosemicarbazone lapachol, which acts on the plasma membrane (0.01–0.1 µM) [40]; azasterol analogs (0.5–10 µM) [41] and hydrazone derivatives (0.1–5 µM) [42], as inhibitors of ergosterol biosynthesis. These compounds are less potent when compared to azole derivatives, such as itraconazole with a 0.003–0.05 µM MIC [33]; luliconazole, a topical antifungal repositioned against Paracoccidioides spp. through in vitro assays and with an MIC ranging from 0.0005 to 0.0007 µM [43]; and butaconazole, which is used for the local treatment of vulvovaginal candidiasis and also repositioned against Paracoccidioides spp. with an MIC of 0.001–0.002 µM. Both compounds are inhibitors of the ergosterol biosynthesis, indicating that this molecular target is very promising. Antimicrobial peptides have also been proposed as potent inhibitors of Paracoccidioides spp., such as MK58911, a peptide analogue of mastoparan, which presented an MIC of 7.8 μg/mL against P. brasiliensis and 15.6 μg/mL against P. lutzii [44]. Lactoferrin-derived peptides presented MIC values between 0.63 and 1.25 μg/mL [45]. The medicinal potential of plants as antifungals comes from their extracts, essential oils, and chemical constituents [46]. Several studies have reported compounds with antifungal properties against PCM, such as argentilactone derived from Hyptis ovalifolia [47], oenothein B derived from Eugenia uniflora [48,49], fatty acid methyl esters and compounds derived from Annona cornifolia essential oils [50], hydroalcoholic extracts from the species Piper regnellii and Baccharis dracunculifolia [51,52], and curcumin from Curcuma longa [53]. Another natural compound is ajoene, derived from Allium sativum, which exerts inhibitory effects against morphological transition and in yeast cells, with possible involvement in the sulfhydryl metabolism of P. brasiliensis [54]. Exploring the universe of natural source compounds, microorganism-derived compounds were tested against Paracoccidioides spp. (Table S2). The extracts and cytochalasin E isolated from Aspergillus felis presented an MIC of 31.2 µg/mL (3.6 µM) [55]. The extract of the endophytic fungus Fusarium sp. containing T2-toxin was able to inhibit clinical strains of P. brasiliensis with an MIC ranging between 75 and 640 nM and the extract containing 8-n-butyrylneosolaniol and 8-isobutyrylsolaniol had MIC values from 160 to 640 nM [56]. Altenusin, isolated from the endophytic fungus Alternaria sp., exhibited an MIC between 1.9 and 31.2 μg/mL [57]. Another important compound is farnesol, a C. albicans quorum sensing molecule, which acts as a potent antifungal inhibiting the growth and dimorphism in μM concentrations [58]. 4. Compounds with Fungicidal Activity The establishment of PCM depends on two fundamental factors—the virulence of the infectious agent and the host’s immune response capacity. After infection, the fungus can remain latent in the host without causing symptoms and the control of fungal replication is dependent on an effective immune response with the activation of CD4 and CD8 T lymphocytes and macrophages [59]. However, fungal cells persist inside granulomas, and when the individual for some reason has a compromised immune system the infection spreads throughout the body, instilling the most severe form that evolves rapidly and with a higher mortality rate [14]. Some definitions are attributed to antifungals, considering the effect on the fungus. Thus, drugs that inhibit fungal growth are considered fungistatic, while drugs that actually cause death are considered fungicides [60]. Studies comparing treatment in co-infected patients with patients only infected with the fungus showed that the recurrence of PCM was greater in patients with HIV, because the antifungal drugs only inhibited the growth of the fungus once the compromised immune system was unable to fight the fungus [61]. Among the therapeutic arsenal used in the treatment of PCM, the only drug reported with fungicidal activity in Paracoccidioides spp. is AmB, which is indicated in the most severe cases of the disease at a dose of 1 mg/kg/day [14]. Due to its low selectivity with systemic toxicity, its antifungal action is overshadowed by serious potentially fatal side effects [62,63]. Experimentally, fungicide concentration tests are used in order to verify the ability of some compounds to promote the effective death of the fungus. The protocol consists of cultivating samples at concentrations above MIC values, in solid culture medium, with the subsequent incubation and visual verification of the fungal growth or inhibition. The minimum fungicidal concentration (MFC) is defined as the lowest concentration of the compound in which the growth of the fungus is not visualized [43]. The technique for defining the fungicidal action of compounds in the fungi of the genus Paracoccidioides date from 1984 [64], when some antimycotic drugs, such as AmB, ketoconazole, and rifampicin, were evaluated against strains of P. brasiliensis where the MFC values were between 0.36 and 500 μg/mL. Some compounds have their MFC values described in Table 1. In general, the compounds are promising, with an acceptable fungicidal potential and selectivity rate. Although the technique for determining the MFC is easy and fast, it is not universally applied. 5. Evaluation of Synergistic Effects of New Compounds Associated with Traditional Antifungals The performance of the clinical antifungals depends on the immunological and physiological status of the patient, hypersensitivity reaction, and pharmacokinetics of such drugs. Combined antifungal therapy (CAT) is an alternative to monotherapy because it increases the spectrum of their activity through the association of antifungals [73]. This approach explores the synergistic interaction of antifungals, and the association might exceed any individual contribution of each drug [74]. Thus, some objectives of CAT are to increase the spectrum of action, reduce the development of fungal resistance, reduce toxicity, and increase fungicidal activity. On the other hand, the association of antifungals might result in antagonistic interactions when the effect of the association is less than the individual effect of each antifungal or results in indifferent interactions when the association is not significant or absent [75,76]. CAT was introduced in the treatment of cryptococcal meningitis in the 1970s [77] and is currently described for the treatment of several fungal infections, including candidiasis [78], aspergillosis [79], and fusariomycosis [80]. However, in the treatment of PCM, this approach is used only for CMX, which is the result of the synergistic association of sulfamethoxazole and trimethoprim [14]. This indication comes from studies carried out in 1982, which reported that the most synergistic effects take place in clinical isolates of P. brasiliensis treated with sulfamethoxazole/trimethoprim in a ratio of 5:1 [31]. The major challenges of the combinatorial therapy are cost and time. Several methodologies evaluate the interaction among antifungal compounds, such as the checkerboard test. This technique combines several concentrations of two compounds arranged in an orderly manner on a microplate. The concentrations of compound (A) decrease in the vertical direction and the concentrations of compound (B) decrease in the horizontal direction, with subsequent incubation with the microorganism under study. The MIC values of the individual compounds are determined in order to identify which compound has the best result. The effect of the interaction results from the Fractional Inhibitory Concentration Index (FICI). It is calculated by the formula FICs = FICA + FICB, where FICA is the MIC of compound A combined with B and then divided by the MIC of compound A alone; FICB is the MIC of compound B combined with A and then divided by the MIC of compound B alone. The FICIs are interpreted as synergic for FIC ≤ 0.5, additive for FIC > 0.5 to ≤1, indifferent effect for FIC > 1 to ≤4, or antagonism for FIC > 4 [81,82]. The association between commercial antifungals and natural and synthetic compounds against Paracoccidioides spp. showed an increase in the potency of the antifungal effect, the association also resulted in a reduction in the concentration of the compounds and the consequent reduction in their toxicity. The synthetic compound CaCS02, an inhibitor of the enzyme chorismate synthase, was identified by bioinformatics tools and demonstrated the synergistic association of CaCS02 with AmB. This interaction reduced the MIC of AmB fourfold (from 0.5 to 0.125 μg/mL) and reduced the MIC of CaCS02 eightfold (from 32 to 4 μg/mL) [65]. The oxadiazole compounds LMM5 and LMM11 showed an additive effect when associated with AmB, resulting in a reduction in the MIC value of AmB from 32 to 4 μg/mL, and the MIC of oxadiazole compounds reduced from 16 to 4 μg/mL [67]. Another study evaluated 17 synthesized compounds derived from 4-methoxynaphthalene-N-acylhydrazones. The compounds 4a-c, 4g, and 4k had synergistic activity with AmB against P. brasiliensis. In addition, the compound 4K was identified as a potential candidate for antifungal therapy in patients co-infected with P. brasiliensis and Mycobacterium tuberculosis [83]. The synergistic association between AmB and copaiba oil was demonstrated in Paracoccidioides spp. and resulted in a reduction in the MIC values from 0.75 to 0.18 μg/mL and from 62.5 to 31.25 μg/mL, respectively [37]. Quinolinyl N-oxide chalcones 3 and AmB or CMX showed synergistic effect and reduced the MIC value of Amphotericin from 0.81 to 0.20 μM and CXM from 9.5 to 0.5 mM [84]. ITZ and synthetic compounds inhibitors of the enzyme homoserine dehydrogenase (HS1 and HS2) showed an additive effect against P. brasiliensis and P. lutzii; the ITZ MIC reduced from 0.008 to 0.001 [85]. Antifungals can interact directly with phagocytic cells (monocytes/macrophages and neutrophils). This interaction might promote synergistic and antagonistic effects during antifungal therapy. The exposure of immune cells to drugs leads to the activation of membrane receptors, culminating in a positive regulation of pro-inflammatory responses [86]. ArtinM, extracted from the seeds of Artocarpus heterophyllus, showed immunomodulatory activity, inducing IL-12 production and Th1-type immune response polarization in rats infected with P. brasiliensis. This last approach resulted in a reduced fungal load [87]. Antifungal drugs induce immunomodulatory activity, such as AmB, which interferes with the secretion of pro-inflammatory chemokines and cytokines [88]. An exacerbated increase in the host’s inflammatory response results in tissue damage and further worsens the patient’s health. The concomitant use of antifungal therapy with corticosteroids in patients with severe forms of PCM results in clinical improvement and prevent complications [89]. The additive effect of the association of chemotherapy with immunizing peptides reduces the treatment time and improves the prognosis of anergic cases [90,91]. The interaction analysis is a promising tool for screening synergistic or antagonistic interactions and should be applied in the identification of new compounds. Thus, combinatorial antifungal therapy is a potential alternative for the treatment of PCM and other invasive infections. 6. Computational Methods: A Potential and Strategic Way to Identify Novel Antifungals The development of new drugs is a complex and expensive process that requires long time and high investment from pharmaceutical industries [92]. The computational approach plays an important role in drug research and development, reduces time and cost by filtering large libraries of compounds into smaller sets that can be tested experimentally, and guides the optimization of the affinity and pharmacokinetic properties of the selected compounds [93]. The development of new approaches could enable a more efficient and rapid treatment and fewer side effects. The choice of therapeutic targets that are absent in humans may result in less toxic effects [94]. Thus, docking and molecular dynamics approaches for the identification of new promising compounds against PCM have been proposed since 2014, exploring the interaction between argentilactone and isocitrate lyase based on molecular dynamics and docking [95]. Costa et al. performed a virtual screening analysis of natural compounds in 2015. This approach used the ZINC database -http://zinc15.docking.org- which contains more than 89 thousand active compounds against the enzyme malate synthase of Paracoccidioides spp. [96]. Promising inhibitors compounds against the enzyme isocitrate lyase were found in a virtual screening approach using the AutoDock Vina program and the ZINC databank. The virtual screening was performed under two conditions (with and without Mg2+) and, among the compounds tested in vitro, the most promising one with antifungal activity and a 100% inhibition of the enzyme activity was from ligands selected from isocitrate lyase bound to Mg+ [66]. This approach points to the importance of considering enzyme cofactors for the computational analysis, minimizing the conditions used in experimental tests. Abadio et al. [68] screened compounds from Life Chemicals -https://lifechemicals.com- with the ability to bind to the enzyme thioredoxin. Out of the 12 compounds selected for the in vitro tests, three showed antifungal activity against Paracoccidioides spp. and, among these, two inhibited the recombinant thioredoxin. Molecular docking simulations identified potential inhibitors of the enzyme homoserine dehydrogenase (HSD) from P. brasiliensis. Four compounds were selected to be tested in vitro [85]. Rodrigues-Vendramini et al. used homology modeling, virtual screening, and molecular dynamics to analyze the P. brasiliensis chorismate synthase (AutoDock and Molegro [97]) in order to identify new potential inhibitors against this enzyme. The study identified of a new compound with potent antifungal activity and that was able to reduce pulmonary inflammation [98]. The shape-based screening methodology identified new anti-Paracoccidioides compounds in 2018. Compounds that share similarity in molecular shape and volume could also share similarity regarding the biological activity. Hence, the virtual screening of chalcone-specific pharmacophores with known antifungal activity was carried out. This approach allowed the selection of 31 compounds with antifungal activity and with an additive effect in combination with AmB [84]. Drug repurposing is a strategy for identifying new therapeutic uses for approved or investigational drugs that are outside the scope of the original medical indication [99,100]. In 2019, two studies applied the drug repositioning method to suggest compounds for the treatment of PCM. In the first, researchers used as scaffold compounds with antifungal activity already described for C. albicans (LMM5 and LMM11) [101]. After applying the Tanimoto coefficient and molecular docking, the antiviral raltegravir was identified as a potent inhibitor of Paracoccidioides spp. [102]. A different approach applied data from the genome of Paracoccidioides spp. to identify orthologous proteins within data banks of compounds [43]. According to this methodology, proteins with a high similarity may share the same ligands. Hence, they performed a screening of orthologous proteins belonging to three isolates of Paracoccidioides spp. against two drug banks (DrugBank and Therapeutic Targets Database). After the comparison of essential S. cerevisiae genes and Paracoccidioides genes we performed homology modeling and molecular docking. Several commercially approved compounds or compounds undergoing clinical trials were selected for the in vitro tests, such as mebendazole, an anti-helminthic drug that has been proposed as a treatment against mycosis caused by Cryptococcus neoformans [103]; azoles, such as sertaconazole, butaconazole, and luliconazole and inhibitors of PbTOR2, such as BGT-226, vistusertib and dactolisib. A perspective for the identification of new anti-Paracoccidioides compounds is the use of computational methods of the type QSAR (Quantitative Structure–Activity Relationship), which is based on mathematical models that predict the biological activity of compounds from the relationships established between chemical structure and biological activity [104,105]. This bioinformatics tool enables the prediction of activity, properties, and toxicity of new compounds [106]. The construction of predictive models is highly dependent on the size, quality, and diversity of the data [107]. The limited number of compounds with biological activity known against Paracoccidioides spp. and the lack of standardization of MIC assays have limited the use of this methodology computational, which requires as input data MIC values and a large number of compounds [105]. 7. The Identification of the Mode of Action of Compounds Based on Ohmics Tools There is an increasing demand for new techniques to unravel the fungal pathogenesis, host–pathogen interplay, and eventually new treatment approaches. Genomics [108], transcriptomics [109], proteomics [110], chemoproteomics [111], and metabolomics [112] contribute to the discovery of new promising compounds with antifungal properties. The host-pathogen interaction leads the onset of the PCM infection [113] and the host and fungal responses drive the investigation of new strategies to combat the disease. Proteomic approaches provide insight into the Paracoccidioides infection on host metabolism, such as the immune response and the pathways involved in fighting the infection, and are able to identify targets in order to intensify defense mechanisms [114]. They also provide insight into the metabolism of the pathogen, pointing to novel virulence factors, mechanisms of action of fungal proteins, and new anti-virulence strategies to improve the treatment of the disease [115]. The first transcriptomic study regarding fungal response in the presence of antifungal prototypes shed some light on how such compounds may interfere with the pathogen survivability within the host and the results confirmed that the compound alters Paracoccidioides cell morphology [48,49]. Although they evidenced that the mode of action of oenothein B is based on the disruption of the cell wall, several other genes related to metabolism, energy, morphology, transcription, and transport were differentially expressed [48] and could potentially lead to new targets. ITZ has been used to treat several fungal infections, including PCM. The mechanism of action of azole antifungal agents is based on the inhibition of ergosterol, which presents roles in the regulation of membrane structure and vesicle formation [116]. The transcriptomic response of Paracoccidioides cells treated with ITZ revealed that genes involved in ergosterol production, cellular transport, energy, transcription, cell rescue, defense, and virulence were differentially expressed [117]. The mode of action of ITZ on Paracoccidioides cells upregulates acetyl synthesis through several pathways, mainly beta-oxidation and amino acid degradation, and drives those molecules to ergosterol production. This same pattern has been found in the ohmic approaches of ITZ on other fungi species, such as Saccharomyces cerevisiae [118] and C. albicans [119]. Interestingly, ITZ drives a detoxification response via the increased expression of glutathione S-transferases and heat shock proteins (HSPs) in Paracoccidioides. The mode of action of argentilactone against that pathogen was investigated in 2015, 2016, and 2018 by proteomics [120], transcriptomics [115], and chemoproteomics [47], respectively. Some common results of those three techniques can be evidenced. The proteomic and transcriptional profile of Paracoccidioides in response to the antifungal argentilactone showed an increase in the levels of stress-related proteins, such as the HSPs. In addition, the argentilactone chemoproteomic approach identified that this natural compound interacts with several HSPs [47]. These results, identified by ohmic studies regarding the mode of action of the new antifungal, suggest that Paracoccidioides HSPs are good targets of stress-inducing compounds (Figure 3). The enzyme superoxide dismutase (SOD) presented increased levels in the proteomic and transcriptional profiles and interacted with the compound in the chemoproteomic approach of Paracoccidioides in the presence of argentilactone [47,115,120]. Thus, it is wise to state that the compound main mode of action is via increasing the stress conditions in the environment where the pathogen cells struggle to survive during the infection. Increasing the expression of SOD seems to be the first antioxidant defense against reactive species in Paracoccidioides spp. [121]. The proteomic profile indicated a remodeling of the carbohydrate metabolism in Paracoccidioides cells treated with argentilactone through a reduced expression of glycolytic enzymes [120]. The transcriptional profile identified that carbon metabolism is inhibited by argentilactone [115] and the chemoproteomic approach showed that the natural compound interacts with GAPDH, influencing the obtainment of energy by the fungal cells [47]. Interestingly, the proteomic results pointed that glucose consumption was reduced by the action of argentilactone and thus, glycolysis was partially blocked [120]. Thus, the ohmic techniques were complementary and together defined the mode of action of these compounds in Paracoccidioides spp. The same path was taken to identify the mode of action of thiosemicarbazide (TSC). The transcriptomics results of Paracoccidioides cells treated with TSC showed that the compound induced the production of reactive species that lead to disruption of the mitochondrial membrane integrity. The immediate consequence for the pathogen cells under such condition was the impairment of TCA, fatty acid oxidation urea cycle, and amino acid metabolism [119,120]. The proteomic profile of Paracoccidioides under TSC treatment identified that the TSC mode of action occurs by the reduction in pyruvate and acetyl-CoA production, besides the reduction in glycolytic and TCA protein/gene levels. Thus, energy generation is severely impaired in the presence of TSC. Interestingly, proteins from the electron transport chain showed increased expression and, conversely, proteins related to respiration showed reduced levels of expression. This leads to the accumulation of electrochemical energy in the mitochondrion membrane and a consequent increase in reactive species. Eventually, ATP production is blocked in the pathogen cells treated with TSC [114]. TSC increases the levels of such species in Paracoccidioides [122].The mode of action of classic antifungals—azoles, for example—also features the production of reactive species [123]. TSC was found to be interacting with HSPs in the chemoproteomic approach and in both approaches, proteomic and transcriptomic, HSPs were found with reduced levels of expression, indicating that cells treated with TSC do not respond well to stress conditions. Thus, the results of proteomics, transcriptomics and chemoproteomic are similar and have driven the identification of its mode of action. All these results combined pointed to important protein targets of TSC. 8. Models for In Vivo Experiments Animal models have been largely used, and they contribute with invaluable information regarding scientific knowledge. Preclinical investigations with the aid of such models have increased the understanding of most diseases that affect human beings. Several animal models have been successfully used either to test the response of the pathogen in the presence of classical antifungals or to predict the pathogen and host responses to new prototype drugs against PCM [124]. Regarding classic antifungal drugs, sulfonamides was proved to be effective in a guinea pig model against PCM [125]. Ketoconazole was successfully tested in mice, rats, hamsters, and guinea pigs [126], reducing the severity of lesions caused by the pathogen. The latter antifungal was more effective in guinea pigs and rats than in hamsters [127]. ITZ was tested in mice, rats, and guinea pigs, and it was more effective than fluconazole [126,128]. Saperconazole was also tested in animal models and in humans [129]. In another murine evaluation, the natural compound ajoene was effective in regulating Paracoccidioides cells growth [130], and the association of ajoene with sulfamethoxazole/trimethoprim was even more effective regarding the reduction in fungal burden [131]. Biochemical features were assessed in mice models of Paracoccidioides under treatment with the compound canova, which is a natural compound extracted from Aconitum napellus and Arsenicum album. Mice treated with canova developed fewer functional alterations in organs affected by the pathogen [132]. There is no doubt that mice are the most used model for testing PCM. However, ethical issues have limited their use and invertebrate animals have been suggested as a viable alternative to decrease the use of mammals in experiments due to ease of manipulation, low cost, and efficiency in the time employed [133]. A new animal model tested for Paracoccidioides pathogenesis was Caenorhabditis elegans. C. elegans in contact with Paracoccidioides was able to stimulate the expression of antimicrobial peptide genes. A different approach tested a synthetic peptide originated from Pichia anomala killer toxin. The antifungal activity of the peptide was assessed in mice and the results were evaluated by immunohistochemistry, showing that animals treated with the peptide presented fewer severe lesions and no fungal cells were found in the lungs of the hosts. The study concluded that such antimicrobial peptides could be applied as an adjuvant to the PCM regular therapy in order to decrease the period of treatment, which normally reaches years [134]. Galleria mellonella is the alternative model most often employed [135,136], since the innate immune response exhibits many structural and functional similarities when compared to the mammalian innate immune response [137]. Not many antifungals have been tested in this model against PCM so far, but the number of studies has increased over the last years and the results have led to a better understanding of the host–pathogen interaction and their response to new prototype drugs. ITZ and AmB were used in a G. mellonella model to assess the efficacy and toxicity of these classical drugs. They showed that both antifungals were effective leading to a higher rate of larval survival and reduced fungal load in the host [113]. Four peptides derived from phage and with anti-adhesive properties were tested for the ability to protect G. mellonella from infection by Paracoccidioides spp. The authors showed that these peptides increased the survival of larvae infected with P. brasiliensis and P. lutzii and suggested that anti-adherence therapy may be an important strategy to prevent PCM [138]. 9. The Important Role of Nanotechnology in the Optimization of Antifungals The clinical effectiveness of a drug depends on the bioactive properties and its local bioavailability. Several nanotechnological applications, including the use of nanoparticles, nanoemulsions, and nanocapsules have been used in the pharmaceutical areas in order to increase the efficiency of bioactive compounds and reduce their therapeutic doses [139]. Classic antifungals used in the treatment of PCM are the targets of optimization projects through nanotechnology (Table S3). ITZ was encapsulated in polymeric nanoparticles composed of poly (D, L-lactide-co-glycolide) (PLGA), which provided a change in its contact surface, altered its bioavailability, and allowed the drug to act as a fungicide in a reduced dose, thus increasing its effectiveness. The initial MIC of ITZ-NANO was 6.25 µg/mL, however its efficiency was increased after 30 days with an MIC value of 0.8 µg/mL and after 60 days with an MIC value of 0.4 µg/mL [140]. Since 1980, lipid-based formulations of AmB have been developed in order to decrease toxicity. The main formulations tested were liposomal AmB, AmB lipid complex, and colloidal AmB dispersion [141]. Hence, new methodological approaches using nanotechnology have been developed with the aim of proposing new formulations of AmB. A formulation of poly(lactide-co-glycolide) (PLGA) or poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) blend nanoparticles containing AmB was developed and resulted in greater antifungal action, decreased nephrotoxicity, and increased bioavailability [142]. In addition, it was able to decrease the number of administrations of the compound in in vivo models [143]. A nanocomplex comprising AmB loaded on the surface of magnetite nanoparticles pre-coated with a double layer of lauric acid exhibited potential antifungal activity with low cytotoxicity and no cytotoxicity to human urinary cells [144]. The association of dodecyl gallate with a nanostructured lipid system (NLS) showed promising antifungal activity and low toxicity in lung fibroblasts and zebrafish embryos [145]. A nanoemulsion composed of 10% oil phase (cholesterol), 10% surfactant (castor oil, polyoxyl60/PEG-hydrogenated, phosphatidylcholine), and sodium oleate was developed with the purpose of potentiating the effects of the antifungal 2-hydroxychalcone. The results were promising, with a high antifungal activity and selective index value. Furthermore, no toxicity was observed in the MIC concentrations in in vivo experiments [146]. Dodecyl protocatechuate, derived from an acid present in fruits, nuts, and vegetables, was conjugated with NLS and increased its antifungal action against P. brasiliensis and P. lutzii and its antioxidant activity. In addition, it was able to decrease its dosage and side effects [147]. Another natural compound which had reduced cytotoxic activity and increased solubility was Copaifera langsdorffii oil in the form of nanoemulsion [37]. 10. What Is the Fate of the Identified Compounds? A Patent Review Despite several published articles indicating new potent compounds, no new drugs have been added to PCM’s therapeutic arsenal in recent years. Therefore, in order to understand where these compounds described in the literature are being directed, we also reviewed the number of existing patents for the treatment of PCM. The search was carried out between July and September 2020 in patent banks, such as INPI-www.inpi.gov.br, Latipat-lp.espacenet.com, Espacenet-worldwide.espacenet.com, and Patentscope-https://patentscope.wipo.int/search/pt/search.jsf, with the following terms “Paracoccidioidomycosis” and “Paracoccidioides spp.” in Portuguese, Spanish, and English. Several patents suggested compounds and peptide as new forms of PCM treatment (Table S4). Vaccine patents and diagnostic tests, even when produced specifically for Paracoccidioides spp., were not taken into consideration. Patents with the same title but with different deposit numbers and/or publication dates were considered only once. Some patents were not produced specifically for the PCM treatment; however, as the patent authors suggested that their products could be used to combat fungi, including Paracoccidioides spp., these patents were considered. We found 74 patents deposited by universities, mainly from Brazil and pharmaceutical companies. The patents encompass new synthetic compounds derived from natural compounds, compounds in nanoparticle formulations, peptides, and injectable pharmaceutical compositions. Although some of the patents are not specific to Paracoccidioides spp., the inventors of the patents suggested their use in the treatment of PCM, such as nikkomycin Z, a modified-nucleoside analog and inhibitor of the chitin synthesis of dimorphic fungal pathogens. Thus, since the cell wall is an important virulence factor of Paracoccidioides spp. and absent in human cells, this compound can be a therapeutic alternative in the treatment of PCM. Despite the expressive number of patents filed over the last years for the treatment of PCM, these patents do not reflect the compounds suggested in the literature. In addition, few patents filed by the pharmaceutical industry cited PCM as their main focus, however these compounds and formulations could be an alternative for the treatment of PCM. 11. Conclusions Given the importance of the development of antifungals against PCM, due to the lack of ideal therapeutic options this review shows that there are still major challenges to be overcome between the discovery of new compounds and the development of antifungals that could be used clinically. However, some researchers have proposed effective drugs with reduced side effects for humans. More research should be carried out in order to achieve treatments that decrease the risk of possible sequelaes of PCM, such as pulmonary fibrosis. In addition, it is necessary to fill the gap between the scientific publication of the biological activity of compounds and the continuation of research in the next stages of the drug development process, such as clinical tests. Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Supplementary Materials The following are available online at https://www.mdpi.com/2309-608X/6/4/300/s1: Table S1: Antifungal derived from synthetic and semi-synthetic compounds tested against Paracoccidioides spp., Table S2: Antifungal compounds derived from plants and microorganisms’ sources tested against Paracoccidioides spp., Table S3: Antifungal compounds within nanoparticle tested against Paracoccidioides spp., Table S4: Patents required to Paracoccidioidomycosis treatment. Click here for additional data file. Author Contributions L.d.C.S. and M.P. idealized and structured the review. M.A.B.C.J. wrote the topic 1 and 2. L.d.C.S. wrote the topic 3. O.B.R. wrote the topic 4. T.G.S. wrote the topic 5. A.A.d.O., D.R.d.S. and R.M.L. wrote the topic 6. K.L.B.B. wrote the topic 7 and 8. K.S.F.eS. wrote the topic 9. A.A.d.O. wrote the topic 10. C.M.d.A.S. revised the manuscript. All authors have read and agreed to the published version of the manuscript. Funding This work was performed at Universidade Federal de Goiás supported by MCTI/CNPq (Ministério da Ciência e Tecnologia/Conselho Nacional de Desenvolvimento Científico e Tecnológico), FNDCT (Fundo Nacional de Desenvolvimento Científico e Tecnológico), FAPEG (Fundação de Amparo à Pesquisa do Estado de Goiás), CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior/Finance Code 001), FINEP (Financiadora de Estudos e Projetos), PRONEX (Programa de Apoio a Núcleos de Excelência), and INCT-IPH (Instituto Nacional de Ciência e Tecnologia de Estratégias de Interação Patógeno-Hospedeiro). Conflicts of Interest The authors declare no conflict of interest. Figure 1 Important events related to the treatment and establishment of a consensus on Paracoccidioidomycosis. Figure 2 Methodologies used in the search and evaluation of anti-paracoccidioidomycosis compounds. MIC (Minimal Inhibitory Concentration), SAA (Synergistic Activity Assay), MFC (Minimal Fungicidal Activity), RSVS (Receptor shape-based Virtual Screening), LSVS (Ligand shape-based Virtual Screening). Figure 3 Modes of action of argentilactone and camphene thiosemicarbazide in Paracoccidioides. The diagram shows the two natural compounds that have been tested in Paracoccidioides cells according to three different ohmic approaches (proteomics, transcriptomics, and chemoproteomics). The central circle shows the common ways both compounds act in the pathogen; both restrict the ability of cells to produce energy through several pathways and, regarding stress conditions, the difference is that while thiosemicarbazide leads to a reduced HSP levels, argentilactone acts in such a way that protein/gene levels are increased. The green color indicates downregulation and the red color indicates upregulation. SOD—superoxide dismutase; ROS—reactive oxygen species; TCA—tricarboxylic acid; ETC—electron transport chain; GAPDH—glyceraldehyde-3-phosphate dehydrogenase. jof-06-00300-t001_Table 1Table 1 Most potent fungicidal compounds. Compounds Target MFC Ref. Identified by virtual screening CaCS02 Chorismate synthase 32 µg/mL [65] ZINC4559339 Isocitrate lyase 7.3–15.6 µg/mL [66] Oxadiazol LMM5 Thioredoxin reductase 1–32 μg/mL [67] Oxadiazol LMM11 Thioredoxin reductase 8–16 μg/mL [67] F3307-0100 Thioredoxin reductase 16.9 µM [68] HS7 (Zinc15967722) Homoserine dehydrogenase 32 μg/mL [69] HS9 (Zinc2123137) Homoserine dehydrogenase 8 μg/mL [69] Identified by drug repositioning Vistusertib Phosphatidylinositol 3-kinase TOR2 1.0–4.2 μM [43] Mebendazole Tubulin beta chain 13.2–26.4 μM [43] Butoconazole Lanosterol 14-alpha demethylase 0.001–0.002 µM [43] Luliconazole Lanosterol 14-alpha demethylase 0.0013–0.0026 µM [43] ENMD-2076 Serine/threonine-protein kinase 7.4–14.8 µM [43] Plant derivatives Hyptis ovalifolia/Argentilactone Isocitrate lyase 4.5–36 μg/mL [47] Eugenia uniflora/oenothein B Beta-glucana sintase 125–500 μg/mL [70] Schinus terebinthifolius/Schinol ND 7.5–125 μg/mL [71] Baccharis dracunculifolia/Caryophyllene oxide ND 125–250 μg/mL [52] Annona cornifolia ND 2–250 µg/mL [72] Copaifera langsdorffii ND 62.5 µg/mL [37] Fungal derivatives Candida albicans/Farnesol Cytoplasmic degeneration 30 µM [58] Aspergillus felis/Cytochalasin E Cell wall 7.2 µM [55] MFC—minimum fungicidal concentration; ND—not determined. ==== Refs References 1. Lutz A. Uma micose pseudococcídica localizada na boca e observada no Brasil. Contribuição ao conhecimento das hifoblastomicoses americanas Adolpho Lutz—Dermatologia e Micologia Editora FIOCRUZ Rio de Janeiro, Brazil 2004 Volume 1 620 85-7541-042-3 2. Marques S.A. Paracoccidioidomicose: Centenário do primeiro relato de caso An. Bras. Dermatol. 2008 83 271 273 10.1590/S0365-05962008000300014 3. Lacaz C.S. Historical Evolution of the Knowledge on Paracoccidioidomycosis and its Etiologic Agent, Paracoccidioides Paracoccidioidomycosis Franco M. da S. Lacaz C. Restrepo-Moreno A. del Negro G. CRC Press Boca Ratón, FL, USA 1994 1 22 4. Rodrigues M.L. Albuquerque P.C. Searching for a change: The need for increased support for public health and research on fungal diseases PLoS Negl. Trop. Dis. 2018 12 e0006479 10.1371/journal.pntd.0006479 29902170 5. Shikanai-Yasuda M.A. Paracoccidioidomycosis treatment Ver. Inst. Med. Trop. São Paulo 2015 57 31 37 10.1590/S0036-46652015000700007 26465367 6. Mendes R.P. Cavalcante R.S. Marques S.A. Marques M.E.A. Venturini J. Sylvestre T.F. Paniago A.M.M. Pereira A.C. da Silva J.D.F. Fabro A.T. Paracoccidioidomycosis: Current Perspectives from Brazil Open Microbiol. J. 2017 11 224 282 10.2174/1874285801711010224 29204222 7. Saleem H. Maryam A. Bokhari S.A. Ashiq A. Rauf S.A. Khalid R.R. Qureshi F.A. Siddiqi A.R. Design, synthesis, characterization and computational docking studies of novel sulfonamide derivatives EXCLI J. 2018 17 169 180 10.17179/excli2017-886 29743855 8. Chen J. Xie S. Overview of sulfonamide biodegradation and the relevant pathways and microorganisms Sci. Total Environ. 2018 640–641 1465 1477 10.1016/j.scitotenv.2018.06.016 9. Adler-Moore J.P. Gangneux J.-P. Pappas P.G. Comparison between liposomal formulations of amphotericin B Med. Mycol. 2016 54 223 231 10.1093/mmy/myv111 26768369 10. Laniado-Laborín R. Cabrales-Vargas M.N. Amphotericin B: Side effects and toxicity Rev. Iberoam. Micol. 2009 26 223 227 10.1016/j.riam.2009.06.003 19836985 11. Kyriakidis I. Tragiannidis A. Munchen S. Groll A.H. Clinical hepatotoxicity associated with antifungal agents Expert Opin. Drug Safety 2017 16 149 165 10.1080/14740338.2017.1270264 12. Barbosa W. Vasconcelos W.M.D.P. Ação da sulfametoxazol associada ao trimetoprim na terapêutica da blastomicose sul-americana J. Trop. Pathol. 1973 329 339 10.5216/rpt.v2i3.22726 13. Capasso C. Supuran C.T. Dihydropteroate synthase (sulfonamides) and dihydrofolate reductase inhibitors Bacterial Resistance to Antibiotics—From Molecules to Man John Wiley & Sons Ltd Hoboken, NJ, USA 2019 163 172 978-1-119-59352-2 14. Shikanai-Yasuda M.A. Mendes R.P. Colombo A.L. de Queiroz-Telles F. Kono A.S.G. Paniago A.M.M. Nathan A. do Valle A.C.F. Bagagli E. Benard G. Brazilian guidelines for the clinical management of paracoccidioidomycosis Rev. Soc. Bras. Med. Trop. 2017 50 715 740 10.1590/0037-8682-0230-2017 28746570 15. Smilack J.D. Trimethoprim-sulfamethoxazole Mayo Clin. Proc. 1999 74 730 734 10.4065/74.7.730 10405706 16. Allen D. Wilson D. Drew R. Perfect J. Azole antifungals: 35 years of invasive fungal infection management Expert Rev. Anti Infec. Ther. 2015 13 787 798 10.1586/14787210.2015.1032939 25843556 17. Gupta A.K. Lyons D.C.A. The rise and fall of oral ketoconazole J. Cutan. Med. Surg. 2015 19 352 357 10.1177/1203475415574970 25775613 18. Negroni R. Robles A.M. Arechavala A. Tuculet M.A. Galimberti R. Ketoconazole in the treatment of paracoccidioidomycosis and histoplasmosis Rev. Infect. Dis. 1980 2 643 649 10.1093/clinids/2.4.643 6255544 19. Cucé L.C. Wroclawski E.L. Sampaio S.A. Treatment of paracoccidioidomycosis, candidiasis, chromomycosis, lobomycosis, and mycetoma with ketoconazole Int. J. Dermatol. 1980 19 405 408 10.1111/j.1365-4362.1980.tb03740.x 6252105 20. Restrepo A. Stevens D.A. Gómez I. Leiderman E. Angel R. Fuentes J. Arana A. Mejía G. Vanegas A.C. Robledo M. Ketoconazole: A new drug for the treatment of paracoccidioidomycosis Rev. Infect. Dis. 1980 2 633 642 10.1093/clinids/2.4.633 6255543 21. Yan J.Y. Nie X.L. Tao Q.M. Zhan S.Y. Zhang Y.D. Ketoconazole associated hepatotoxicity: A systematic review and meta- analysis Biomed. Environ. Sci. 2013 26 605 610 10.3967/0895-3988.2013.07.013 23895707 22. Negroni R. Palmieri O. Koren F. Tiraboschi I.N. Galimberti R.L. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans Rev. Infect. Dis. 1987 9 Suppl. 1 S47 S50 10.1093/clinids/9.Supplement_1.S47 3027846 23. Ollague J.M. Zurita A.M.D. Calero G. Paracoccidioidomycosis (South American blastomycosis) successfully treated with terbinafine: First case report Br. J. Dermatol. 2000 143 188 191 10.1046/j.1365-2133.2000.03614.x 10886159 24. Visbal G. San-Blas G. Murgich J. Franco H. Paracoccidioides brasiliensis , paracoccidioidomycosis, and antifungal antibiotics Curr. Drug Targets Infect. Disord. 2005 5 211 226 10.2174/1568005054880118 16181141 25. Telles F.Q. Goldani L.Z. Schlamm H.T. Goodrich J.M. Ingroff A.E. Yasuda M.A.S. An Open-Label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis Clin. Infect. Dis. 2007 45 1462 1469 10.1086/522973 17990229 26. Andrade U.V. Oliveira S.M. Chang M.R. Pereira E.F. Marques A.P. de Carvalho L.R. Mendes R.P. Paniago A.M.M. Andrade U.V. Oliveira S.M. Treatment compliance of patients with paracoccidioidomycosis in Central-West Brazil J. Bras. Pneumol. 2019 45 10.1590/1806-3713/e20180167 31017226 27. Costa C. Albuquerque F.C. Andrade R.V. de Oliveira G.C. de Almeida M.F. Brigido M. Maranhão A.Q. Transporters in the Paracoccidioides brasiliensis transcriptome: Insights on drug resistance Genet. Mol. Res. 2005 4 390 408 16110453 28. Hahn R.C. Morato Conceição Y.T. Santos N.L. Ferreira J.F. Hamdan J.S. Disseminated paracoccidioidomycosis: Correlation between clinical and in vitro resistance to ketoconazole and trimethoprim sulphamethoxazole Mycoses 2003 46 342 347 10.1046/j.1439-0507.2003.00901.x 12950907 29. Cermehol J.R. Alvarado P. Mendoza M. Herndndez I. Cuestal D. In vitro susceptibility of isolates of Paracoccidioides spp complex to systemic antifungals using the microdilution method Investig. Clin. 2015 56 243 253 26710539 30. Parente-Rocha J.A. Bailão A.M. Amaral A.C. Taborda C.P. Paccez J.D. Borges C.L. Pereira M. Antifungal resistance, metabolic routes as drug targets, and new antifungal agents: An overview about endemic dimorphic fungi Mediat. Inflam. 2017 2017 1 16 10.1155/2017/9870679 31. Stevens D.A. Vo P.T. Synergistic interaction of trimethoprim and sulfamethoxazole on Paracoccidioides brasiliensis Antim. Agents Chemother. 1982 21 852 854 10.1128/AAC.21.5.852 32. Nakai T. Uno J. Ikeda F. Tawara S. Nishimura K. Miyaji M. In vitro antifungal activity of micafungin (fk463) against dimorphic fungi: Comparison of yeast-like and mycelial forms AAC 2003 47 1376 1381 10.1128/AAC.47.4.1376-1381.2003 33. de Paula e Silva A.C.A. Oliveira H.C. Silva J.F. Sangalli-Leite F. Scorzoni L. Fusco-Almeida A.M. Mendes-Giannini M.J.S. Microplate alamarblue assay for Paracoccidioides susceptibility testing J. Clin. Microbiol. 2013 51 1250 1252 10.1128/JCM.02914-12 23345296 34. Cruz R.C. Werneck S.M.C. Oliveira C.S. Santos P.C. Soares B.M. Santos D.A. Cisalpino P.S. Influence of different media, incubation times, and temperatures for determining the mics of seven antifungal agents against Paracoccidioides brasiliensis by microdilution J. Clin. Microbiol. 2013 51 436 443 10.1128/JCM.02231-12 23175254 35. CLSI CLSI-Clinical and Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, Approved Standard. Document M27 CLSI Wayne, PA, USA 2008 36. de Sá N.P. Cisalpino P.S. Bertollo C.M. Santos P.C. Rosa C.A. de Souza D.G. Barbeira P.J.S. Alves T.M. Zani C.L. Johann S. Thiosemicarbazone of lapachol acts on cell membrane in Paracoccidioides brasiliensis Med. Mycol. 2019 57 332 339 10.1093/mmy/myy045 29945180 37. do Carmo Silva L. Miranda M.A.C.M. de Freitas J.V. Ferreira S.F.A. de Oliveira Lima E.C. de Oliveira C.M.A. Kato L. Terezan A.P. Rodriguez A.F.R. Faria F.S.E.D.V. Antifungal activity of Copaíba resin oil in solution and nanoemulsion against Paracoccidioides spp. Braz. J. Microbiol. 2020 51 125 134 10.1007/s42770-019-00201-3 31833006 38. de Paula e Silva A.C.A. Costa-Orlandi C.B. Gullo F.P. Sangalli-Leite F. de Oliveira H.C. Silva J. Scorzoni L. Pitangui N. Rossi S.A. Benaducci T. Antifungal activity of decyl gallate against several species of pathogenic fungi Evid. Based Complem. Altern. Med. 2014 2014 1 8 10.1155/2014/506273 25505923 39. de Paula e Silva A.C.A. de Oliveira H.C. Scorzoni L. Marcos C.M. dos Santos C.T. Fusco-Almeida A.M. Salina A.C.G. Medeiros A.I. Almeida F. Li S.C. Decyl gallate as a possible inhibitor of n-glycosylation process in Paracoccidioides lutzi Antimicrob. Agents Chemother. 2019 63 e01909-18 10.1128/AAC.01909-18 31451502 40. Souza M.A. Johann S. Lima L.A.R. Campos F.F. Mendes I.C. Beraldo H. de Souza-Fagundes E.M. Cisalpino P.S. Rosa C.A. Alves T.M. The antimicrobial activity of lapachol and its thiosemicarbazone and semicarbazone derivatives Memórias Inst. Oswaldo Cruz 2013 108 342 351 10.1590/S0074-02762013000300013 23778660 41. Visbal G. Alvarez A. Moreno B. San-Blas G. S-Adenosyl-l-Methionine Inhibitors Δ24-Sterol Methyltransferase and Δ24(28)-sterol methylreductase as possible agents against Paracoccidioides brasiliensis AAC 2003 47 2966 2970 10.1128/AAC.47.9.2966-2970.2003 12937003 42. Visbal G. San-Blas G. Maldonado A. Álvarez-Aular Á. Capparelli M.V. Murgich J. Synthesis, in vitro antifungal activity and mechanism of action of four sterol hydrazone analogues against the dimorphic fungus Paracoccidioides brasiliensis Steroids 2011 76 1069 1081 10.1016/j.steroids.2011.04.012 21605581 43. De Oliveira A.A. Neves B.J. Silva L. Soares C.M. Andrade C.H. Pereira M. Drug repurposing for paracoccidioidomycosis through a computational chemogenomics framework Front. Microbiol. 2019 10 1301 10.3389/fmicb.2019.01301 31244810 44. Singulani J.L. Galeane M.C. Ramos M.D. Gomes P.C. dos Santos C.T. de Souza B.M. Palma M.S. Fusco Almeida A.M. Mendes Giannini M.J.S. Antifungal Activity, toxicity, and membranolytic action of a mastoparan analog peptide Front. Cell. Infect. Microbiol. 2019 9 419 10.3389/fcimb.2019.00419 31867293 45. Fernandes K.E. Carter D.A. The antifungal activity of lactoferrin and its derived peptides: Mechanisms of action and synergy with drugs against fungal pathogens Front. Microbiol. 2017 8 10.3389/fmicb.2017.00002 28149293 46. Sortino M. Derita M. Svetaz L. Raimondi M. Di Liberto M. Petenatti E. Gupta M. Zacchino S. The role of natural products in discovery of new anti-infective agents with emphasis on antifungal compounds Plant Bioact. Drug Discov. Princ. Pract. Persp. 2012 4 205 239 10.1002/9781118260005.ch6 47. Silva L.C. Tauhata S.B.F. Baeza L.C. de Oliveira C.M.A. Kato L. Borges C.L. de Almeida Soares C.M. Pereira M. Argentilactone molecular targets in Paracoccidioides brasiliensis identified by chemoproteomics Antimicrob. Agents Chemother. 2018 62 10.1128/AAC.00737-18 30150478 48. Zambuzzi-Carvalho P.F. Tomazett P.K. Santos S.C. Ferri P.H. Borges C.L. Martins W.S. de Almeida Soares C.M. Pereira M. Transcriptional profile of Paracoccidioides induced by oenothein B, a potential antifungal agent from the Brazilian Cerrado plant Eugenia uniflora BMC Microbiol. 2013 13 227 10.1186/1471-2180-13-227 24119145 49. Santos G.D. Ferri P.H. Santos S.C. Bao S.N. Soares C.M.A. Pereira M. Oenothein B inhibits the expression of PbFKS1 transcript and induces morphological changes in Paracoccidioides brasiliensis Med. Mycol. 2007 45 609 618 10.1080/13693780701502108 18033615 50. do Prado A.C. Garces H.G. Bagagli E. Rall V.L.M. Furlanetto A. Fernandes Junior A. Furtado F.B. Schinus molle essential oil as a potential source of bioactive compounds: Antifungal and antibacterial properties J. Appl. Microbiol. 2019 126 516 522 10.1111/jam.14157 30431699 51. Johann S. Cisalpino P.S. Watanabe G.A. Cota B.B. de Siqueira E.P. Pizzolatti M.G. Zani C.L. de Resende M.A. Antifungal activity of extracts of some plants used in Brazilian traditional medicine against the pathogenic fungus Paracoccidioides brasiliensis Pharm. Biol. 2010 48 388 396 10.3109/13880200903150385 20645716 52. Johann S. Oliveira F.B. Siqueira E.P. Cisalpino P.S. Rosa C.A. Alves T.M.A. Zani C.L. Cota B.B. Activity of compounds isolated from Baccharis dracunculifolia D.C. (Asteraceae) against Paracoccidioides brasiliensis Med. Mycol. 2012 50 843 851 10.3109/13693786.2012.678903 22548242 53. Neelofar K. Shreaz S. Rimple B. Muralidhar S. Nikhat M. Khan L.A. Curcumin as a promising anticandidal of clinical interest Can. J. Microbiol. 2011 57 204 210 10.1139/W10-117 21358761 54. San-Blas G. Mariño L. San-Blas F. Apitz-Castro R. Effect of ajoene on dimorphism of Paracoccidioides brasiliensis Med. Mycol. 1993 31 133 141 10.1080/02681219380000151 55. Mendes G. Baltazar L.M. Souza D.G. Sá N.P. Rosa L.H. Rosa C.A. Souza-Fagundes E.M. Ramos J.P. Alves-Silva J. Cota B.B. Effects of cytochalasin E on Paracoccidioides brasiliensis J. Appl. Microbiol. 2018 125 1296 1307 10.1111/jam.14053 30053334 56. Campos F.F. Johann S. Cota B.B. Alves T.M.A. Rosa L.H. Caligiorne R.B. Cisalpino P.S. Rosa C.A. Zani C.L. Antifungal activity of trichothecenes from Fusarium sp. against clinical isolates of Paracoccidioides brasiliensis : Antifungal activity of trichothecenes Mycoses 2011 54 e122 e129 10.1111/j.1439-0507.2009.01854.x 20337937 57. Johann S. Rosa L.H. Rosa C.A. Perez P. Cisalpino P.S. Zani C.L. Cota B.B. Antifungal activity of altenusin isolated from the endophytic fungus Alternaria sp. against the pathogenic fungus Paracoccidioides brasiliensis Rev. Iberoam. Micol. 2012 29 205 209 10.1016/j.riam.2012.02.002 22366718 58. Derengowski L.S. De-Souza-Silva C. Braz S.V. Mello-De-Sousa T.M. Báo S.N. Kyaw C.M. Silva-Pereira I. Antimicrobial effect of farnesol, a Candida albicans quorum sensing molecule, on Paracoccidioides brasiliensis growth and morphogenesis Ann Clin. Microbiol. Antimicrob. 2009 8 13 10.1186/1476-0711-8-13 19402910 59. Benard G. An overview of the immunopathology of human paracoccidioidomycosis Mycopathologia 2008 165 209 221 10.1007/s11046-007-9065-0 18777630 60. Lewis J.S. Graybill J.R. Fungicidal versus Fungistatic: What’s in a word? Expert Opin. Pharmacother. 2008 9 927 935 10.1517/14656566.9.6.927 18377336 61. Machado A.A. Martinez R. Morejón K.M.L. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: A case-control study Amer. J. Trop. Med. Hygiene 2009 80 359 366 10.4269/ajtmh.2009.80.359 62. Harmsen S. McLaren A.C. Pauken C. McLemore R. Amphotericin B is cytotoxic at locally delivered concentrations Clin. Orthop. Related Res. 2011 469 3016 3021 10.1007/s11999-011-1890-2 21484472 63. Sales G.T. Foresto R.D. Drug-induced nephrotoxicity Rev. Assoc. Med. Bras. 2020 66 82 90 10.1590/1806-9282.66.s1.82 64. Restrepo A. Tabares C.B.A.M. In vitro susceptibility of Paracoccidioides brasiliensis yeast form to antifungal agents Rev. Inst. Med. Trop. S. Paulo 1984 26 322 328 10.1590/S0036-46651984000600006 6100138 65. Bueno P.S.A. Rodrigues-Vendramini F.A.V. Toplak M. Macheroux P. Kioshima É.S. Seixas F.A.V. New inhibitors of chorismate synthase present antifungal activity against Paracoccidioides brasiliensis Future Microbiol. 2019 14 969 980 10.2217/fmb-2019-0052 31382783 66. Da Silva L.S. Barbosa U.R. Silva L.D.C. Soares C.M.A. Pereira M. Da Silva R.A. Identification of a new antifungal compound against isocitrate lyase of Paracoccidioides brasiliensis Future Microbiol. 2020 14 1589 1606 10.2217/fmb-2019-0166 31990208 67. Rodrigues-Vendramini F.A.V. Faria D.R. Arita G.S. Capoci I.R.G. Sakita K.M. Caparroz-Assef S.M. Becker T.C.A. de Souza Bonfim-Mendonça P. Felipe M.S. Svidzinski T.I.E. Antifungal activity of two oxadiazole compounds for the paracoccidioidomycosis treatment PLoS Negl. Trop. Dis. 2019 13 e0007441 10.1371/journal.pntd.0007441 31163021 68. Abadio A.K.R. Kioshima E.S. Leroux V. Martins N.F. Maigret B. Felipe M.S.S. Identification of new antifungal compounds targeting thioredoxin reductase of Paracoccidioides genus PLoS ONE 2015 10 e0142926 10.1371/journal.pone.0142926 26569405 69. Bueno P.S.A. Rodrigues F.A.V. Santos J.L. Canduri F. Biavatti D.C. Pimentel A.L. Bagatin M.C. Kioshima É.S. de Freitas Gauze G. Seixas F.A.V. New inhibitors of homoserine dehydrogenase from Paracoccidioides brasiliensis presenting antifungal activity J. Mol. Model. 2019 25 10.1007/s00894-019-4221-2 70. Costa D.P. Filho E.G.A. Silva L.M.A. Santos S.C. Passos X.S. Do Rosário R. Silva M. Seraphin J.C. Ferri P.H. Influence of fruit biotypes on the chemical composition and antifungal activity of the essential oils of eugenia uniflora leaves J. Braz. Chem. Soc. 2010 21 851 858 10.1590/S0103-50532010000500012 71. Johann S. Sá N.P. Lima L.A.R.S. Cisalpino P.S. Cota B.B. Alves T.M.A. Siqueira E.P. Zani C.L. Antifungal activity of schinol and a new biphenyl compound isolated from Schinus terebinthifolius against the pathogenic fungus Paracoccidioides brasiliensis An. Clin. Microbiol. Antim. 2010 9 30 10.1186/1476-0711-9-30 72. Lima L.A.R.S. Alves T.M.A. Zani C.L. Sales Júnior P.A. Romanha A.J. Johann S. Cisalpino P.S. Pimenta L.P.S. Boaventura M.A.D. In vitro cytotoxic, antifungal, trypanocidal and leishmanicidal activities of acetogenins isolated from Annona cornifolia A. St. -Hil. (Annonaceae) An. Acad. Bras. Ciênc. 2014 86 829 839 10.1590/0001-3765201420130048 30514008 73. Belanger E.S. Yang E. Forrest G.N. Combination antifungal therapy: When, where, and why Curr. Clin. Micro. Rep. 2015 2 67 75 10.1007/s40588-015-0017-z 74. Kontoyiannis D.P. Lewis R.E. Toward more effective antifungal therapy: The prospects of combination therapy Br. J. Haematol. 2004 126 165 175 10.1111/j.1365-2141.2004.05007.x 15238137 75. Johnson M.D. Perfect J.R. Use of antifungal combination therapy: Agents, order, and timing Curr. Fungal Infect. Rep. 2010 4 87 95 10.1007/s12281-010-0018-6 20574543 76. Groll A.H. Kolve H. Antifungal Agents: In vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy Eur. J. Clin. Microbiol. Infect. Dis. 2004 23 256 270 10.1007/s10096-004-1108-6 15015031 77. Bennett J.E. Dismukes W.E. Duma R.J. Medoff G. Sande M.A. Gallis H. Leonard J. Fields B.T. Bradshaw M. Haywood H. A Comparison of amphotericin B alone and combined with flucytosine in the treatment of Cryptoccal meningitis N. Engl. J. Med. 1979 301 126 131 10.1056/NEJM197907193010303 449951 78. Vazquez J.A. Combination antifungal therapy against Candida species: The new frontier-are we there yet? Med. Mycol. 2003 41 355 368 10.1080/13693780310001616528 14653512 79. Panackal A.A. Combination Antifungal therapy for invasive aspergillosis revisited Med. Mycol. Open Access 2016 2 1 5 10.21767/2471-8521.100012 80. Liu J.Y. Chen W.T. Ko B.S. Yao M. Hsueh P.R. Hsiao C.H. Kuo Y.M. Chen Y.C. Combination antifungal therapy for disseminated fusariosis in immunocompromised patients: A case report and literature review Med. Mycol. 2011 49 872 878 10.3109/13693786.2011.567304 21449694 81. Cuenca-Estrella M. Combinations of antifungal agents in therapy--what value are they? J. Antimicrob. Chemother. 2004 54 854 869 10.1093/jac/dkh434 15375111 82. Odds F.C. Synergy, antagonism, and what the chequerboard puts between them J. Antim. Chem. 2003 52 1 10.1093/jac/dkg301 83. Rozada A.M. Rodrigues F.A. Sampiron E.G. Seixas F.A. Basso E.A. Scodro R.B. Kioshima É.S. Gauze G.F. Novel 4-methoxynaphthalene- N-acylhydrazones as potential for paracoccidioidomycosis and tuberculosis co-infection Future Microbiol. 2019 14 587 598 10.2217/fmb-2018-0357 31148472 84. Silva L.C. Neves B.J. Gomes M.N. Melo-Filho C.C. Soares C.M. Andrade C.H. Pereira M. Computer-aided identification of novel anti-paracoccidioidomycosis compounds Future Microbiol. 2018 13 1523 1535 10.2217/fmb-2018-0175 30311802 85. Bagatin M.C. Pimentel A.L. Biavatti D.C. Basso E.A. Kioshima E.S. Seixas F.A.V. Gauze G.F. Targeting the homoserine dehydrogenase of Paracoccidioides species for treatment of systemic fungal infections Antimicrob. Agents Chemother. 2017 61 1 13 10.1128/AAC.00165-17 28652239 86. Simitsopoulou M. Roilides E. Walsh T.J. Immunomodulatory properties of antifungal agents on phagocytic cells Immunol. Investig. 2011 40 809 824 10.3109/08820139.2011.615877 21985307 87. Ruas L.P. Genaro L.M. Justo-Junior A.S. Coser L.O. de Castro L.F. Trabasso P. Mamoni R.L. Roque-Barreira M.-C. Blotta M.-H.S.L. Effect of artinm on human blood cells during infection with Paracoccidioides brasiliensis Front. Microbiol. 2018 9 1 13 10.3389/fmicb.2018.00867 29403456 88. Sau K. Mambula S.S. Latz E. Henneke P. Golenbock D.T. Levitz S.M. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism J. Biol. Chem. 2003 278 37561 37568 10.1074/jbc.M306137200 12860979 89. Benard G. Campos A.F. Netto L.C. Gonçalves L.G. Machado L.R. Mimicos E.V. França F.O.S. Gryschek R.C.B. Treatment of severe forms of paracoccidioidomycosis: Is there a role for corticosteroids? Med. Mycol. 2012 50 641 648 10.3109/13693786.2011.654135 22309459 90. Marques A.F. da Silva M.B. Juliano M.A.P. Munhõz J.E. Travassos L.R. Taborda C.P. Additive effect of P10 immunization and chemotherapy in anergic mice challenged intratracheally with virulent yeasts of Paracoccidioides brasiliensis Microb. Infect. 2008 10 1251 1258 10.1016/j.micinf.2008.07.027 91. Travassos L.R. Rodrigues E.G. Iwai L.K. Taborda C.P. Attempts at a peptide vaccine against paracoccidioidomycosis, adjuvant to chemotherapy Mycopathologia 2008 165 341 352 10.1007/s11046-007-9056-1 18777638 92. Pushpakom S. Iorio F. Eyers P.A. Escott K.J. Hopper S. Wells A. Doig A. Guilliams T. Latimer J. McNamee C. Drug repurposing: Progress, challenges and recommendations Nat. Rev. Drug Discov. 2019 18 41 59 10.1038/nrd.2018.168 30310233 93. Lin X. Li X. Lin X. A review on applications of computational methods in drug screening and design Molecules 2020 25 1375 10.3390/molecules25061375 32197324 94. Bocca A.L. Amaral A.C. Teixeira M.M. Sato P.K. Shikanai-Yasuda M.A. Soares Felipe M.S. Paracoccidioidomycosis: Eco-epidemiology, taxonomy and clinical and therapeutic issues Future Microbiol. 2013 8 1177 1191 10.2217/fmb.13.68 24020744 95. do Prado R.S. Alves R.J. de Oliveira C.M.A. Kato L. da Silva R.A. Quintino G.O. do Desterro Cunha S. de Almeida Soares C.M. Pereira M. Inhibition of Paracoccidioides lutzii Pb01 isocitrate lyase by the natural compound argentilactone and its semi-synthetic derivatives PLoS ONE 2014 9 e94832 10.1371/journal.pone.0094832 24752170 96. Costa F.G. Neto B.R.S. Gonçalves R.L. da Silva R.A. de Oliveira C.M.A. Kato L. Freitas C.S. Giannini M.J.S.M. da Silva J.F. Soares C.M.A. Alkaloids as inhibitors of malate synthase from Paracoccidioides spp.: Receptor-ligand interaction-based virtual screening and molecular docking studies, antifungal activity, and the adhesion process Antimicrob. Agents Chemother. 2015 59 5581 5594 10.1128/AAC.04711-14 26124176 97. Thomsen R. Christensen M.H. MolDock: A new technique for high-accuracy molecular docking J. Med. Chem. 2006 49 3315 3321 10.1021/jm051197e 16722650 98. Rodrigues-Vendramini F.A.V. Marschalk C. Toplak M. Macheroux P. Bonfim-Mendonça P.S. Svidzinski T.I.E. Seixas F.A.V. Kioshima E.S. Promising new antifungal treatment targeting chorismate synthase from Paracoccidioides brasiliensis Antimicrob. Agents Chemother. 2018 63 e01097-18 10.1128/AAC.01097-18 30348661 99. Ashburn T.T. Thor K.B. Drug repositioning: Identifying and developing new uses for existing drugs Nat. Rev. Drug Discov. 2004 3 673 683 10.1038/nrd1468 15286734 100. Ekins S. Williams A.J. Krasowski M.D. Freundlich J.S. In silico repositioning of approved drugs for rare and neglected diseases Drug Discov. Today 2011 16 298 310 10.1016/j.drudis.2011.02.016 21376136 101. Capoci I.R.G. Sakita K.M. Faria D.R. Rodrigues-Vendramini F.A.V. Arita G.S. de Oliveira A.G. Felipe M.S. Maigret B. Bonfim-Mendonça P.S. Kioshima E.S. Two new 1,3,4-oxadiazoles with effective antifungal activity against Candida albicans Front. Microbiol. 2019 10 1 11 10.3389/fmicb.2019.02130 30728808 102. Capoci I.R.G. Faria D.R. Sakita K.M. Rodrigues-Vendramini F.A.V. Bonfim-Mendonça P.S. Becker T.C.A. Kioshima É.S. Svidzinski T.I.E. Maigret B. Repurposing approach identifies new treatment options for invasive fungal disease Bioorganic Chem. 2019 84 87 97 10.1016/j.bioorg.2018.11.019 103. Cruz M.C. Bartlett M.S. Edlind T.D. In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles Antim. Agents Chemother. 1994 38 378 380 10.1128/AAC.38.2.378 104. Cherkasov A. Muratov E.N. Fourches D. Varnek A. Baskin I.I. Cronin M. Dearden J. Gramatica P. Martin Y.C. Todeschini R. QSAR modeling: Where have you been? Where are you going to? J. Med. Chem. 2014 57 4977 5010 10.1021/jm4004285 24351051 105. Tropsha A. Best Practices for QSAR Model Development, validation, and exploitation Mol. Inf. 2010 29 476 488 10.1002/minf.201000061 106. Roy K. Mitra I. On various metrics used for validation of predictive QSAR models with applications in virtual screening and focused library design Comb. Chem. High Throughput Screen. 2011 14 450 474 10.2174/138620711795767893 21521150 107. Sansone S.-A. Rocca-Serra P. Field D. Maguire E. Taylor C. Hofmann O. Fang H. Neumann S. Tong W. Amaral-Zettler L. Toward interoperable bioscience data Nat. Genet. 2012 44 121 126 10.1038/ng.1054 22281772 108. Odds F.C. Genomics, molecular targets and the discovery of antifungal drugs Rev. Iberoam. Micol. 2005 22 229 237 10.1016/S1130-1406(05)70048-6 16499416 109. Yang Q. Gao L. Tao M. Chen Z. Yang X. Cao Y. Transcriptomics analysis of candida albicans treated with huanglian jiedu decoction using RNA-seq Evid. -Based Complementary Altern. Med. 2016 2016 1 9 10.1155/2016/3198249 110. Amarsaikhan N. Albrecht-Eckardt D. Sasse C. Braus G.H. Ogel Z.B. Kniemeyer O. Proteomic profiling of the antifungal drug response of Aspergillus fumigatus to voriconazole Int. J. Med. Microbiol. 2017 307 398 408 10.1016/j.ijmm.2017.07.011 28811086 111. Wright M.H. Sieber S.A. Chemical proteomics approaches for identifying the cellular targets of natural products Nat. Prod. Rep. 2016 33 681 708 10.1039/C6NP00001K 27098809 112. Wan C. Li P. Chen C. Peng X. Li M. Chen M. Wang J. Chen J. Antifungal activity of Ramulus cinnamomi explored by 1H-NMR based metabolomics approach Molecules 2017 22 2237 10.3390/molecules22122237 29244766 113. de Oliveira H.C. Assato P.A. Marcos C.M. Scorzoni L. de Paula E Silva A.C.A. Da Silva J.D.F. Singulani J.L. Alarcon K.M. Fusco-Almeida A.M. Mendes-Giannini M.J.S. Paracoccidioides-host Interaction: An overview on recent advances in the Paracoccidioidomycosis Front. Microbiol. 2015 6 1 20 10.3389/fmicb.2015.01319 25653648 114. e Silva K.S. da S Neto B.R. Zambuzzi-Carvalho P.F. de Oliveira C.M. Pires L.B. Kato L. Bailão A.M. Parente-Rocha J.A. Hernández O. Ochoa J.G. Response of Paracoccidioides lutzii to the antifungal camphene thiosemicarbazide determined by proteomic analysis Future Microbiol. 2018 13 1473 1496 10.2217/fmb-2018-0176 30311782 115. Araújo F.S. Coelho L.M. Silva L.C. da Silva Neto B.R. Parente-Rocha J.A. Bailão A.M. de Oliveira C.M.A. Fernandes G.R. Hernández O. Ochoa J.G.M. Effects of argentilactone on the transcriptional profile, cell wall and oxidative stress of Paracoccidioides spp. PLoS Negl. Trop. Dis. 2016 10 e0004309 10.1371/journal.pntd.0004309 26734764 116. Borgers M. Van de Ven M.-A. Mode of action of itraconazole: Morphological aspects Mycoses 1989 32 53 59 10.1111/j.1439-0507.1989.tb02294.x 2561185 117. Neto B.R.S. Carvalho P.F. Bailão A. Martins W. de Almeida Soares C. Pereira M. Transcriptional profile of Paracoccidioides spp. in response to itraconazole BMC Genom. 2014 15 254 10.1186/1471-2164-15-254 24690401 118. Bammert G.F. Fostel J.M. Genome-Wide Expression Patterns inSaccharomyces cerevisiae: Comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterol Antimicrob. Agents Chemother. 2000 44 1255 1265 10.1128/AAC.44.5.1255-1265.2000 10770760 119. Liu T.T. Lee R.E.B. Barker K.S. Lee R.E. Wei L. Homayouni R. Rogers P.D. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans AAC 2005 49 2226 2236 10.1128/AAC.49.6.2226-2236.2005 120. Prado R.S. Bailão A.M. Silva L.C. de Oliveira C.M.A. Marques M.F. Silva L.P. Silveira-Lacerda E.P. Lima A.P. Soares C.M. Pereira M. Proteomic profile response of Paracoccidioides lutzii to the antifungal argentilactone Front. Microbiol. 2015 6 1 14 10.3389/fmicb.2015.00616 25653648 121. Dantas A.S. Andrade R.V. de Carvalho M.J. Felipe M.S.S. Campos É.G. Oxidative stress response in Paracoccidioides brasiliensis : Assessing catalase and cytochrome c peroxidase Mycol. Res. 2008 112 747 756 10.1016/j.mycres.2007.11.018 18499421 122. do Carmo Silva L. Tamayo Ossa D.P. Castro S.V.C. Bringel Pires L. Alves de Oliveira C.M. Conceição da Silva C. Coelho N.P. Bailão A.M. Parente-Rocha J.A. Soares C.M.A. Transcriptome profile of the response of Paracoccidioides spp. to a camphene thiosemicarbazide derivative PLoS ONE 2015 10 e0130703 10.1371/journal.pone.0130703 26114868 123. Delattin N. Cammue B.P. Thevissen K. Reactive oxygen species-inducing antifungal agents and their activity against fungal biofilms Future Med. Chem. 2014 6 77 90 10.4155/fmc.13.189 24358949 124. Hooijmans C.R. Leenaars M. Ritskes-Hoitinga M. A gold standard publication checklist to improve the quality of animal studies, to fully integrate the three rs, and to make systematic reviews more feasible Altern. Lab. Anim. 2010 38 167 182 10.1177/026119291003800208 20507187 125. Peryassú D. O sistema retículo-endotelial na blastomicose brasileira experimental do cobaio. Sua Importancia no Trat. Sulfamídico J. Bras. Med. 1962 503 515 126. Negroni R. Azole derivatives in the treatment of paracoccidioidomycosis Ann. N. Y. Acad. Sci. 1988 544 497 503 10.1111/j.1749-6632.1988.tb40447.x 3063183 127. Mota N.G.S. Viero R.M. Rezkallah-Iwasso M.T. Peraçoli M.T.S. Soares A.M.V.C. Montenegro M.R. The effect of ketoconazole on experimental paracoccidioidomycosis in the syrian hamster: Immunological and histopathological study Mycopathologia 1984 88 141 148 10.1007/BF00436445 6098832 128. Negroni R. Paracoccidioidomycosis (south american blastomycosis, Lutz’s mycosis) Int. J. Dermatol. 1993 32 847 859 10.1111/j.1365-4362.1993.tb01396.x 8125682 129. Van Cutsem J. Van Gerven F. Janssen P.A.J. Saperconazole, a new potent antifungal triazole: In vitro activity spectrum and therapeutic efficacy Drugs Fut. 1989 14 1187 10.1358/dof.1989.014.12.109655 130. Maluf M.L.F. Takahachi G. Svidzinski T.I.E. Xander P. Apitz-Castro R. Bersani-Amado C.A. Cuman R.K.N. Actividad antifúngica del ajoeno en la paracoccidioidomicosis experimental en ratones Rev. Iberoam. Micol. 2008 25 163 166 10.1016/S1130-1406(08)70038-X 18785786 131. Thomaz L. Apitz-Castro R. Marques A.F. Travassos L.R. Taborda C.P. Experimental paracoccidioidomycosis: Alternative therapy with ajoene, compound from Allium sativum, associated with sulfamethoxazole/trimethoprim Med. Mycol. 2008 46 113 118 10.1080/13693780701651681 18324489 132. Takahachi G. Maluf M.L.F. Svidzinski T.I.E. Akimoto-Günther L.S. Hübler M.R.N.O. Bersani-Amado C.A. Cuman R.K.N. Biochemical responses in mice experimentally infected with Paracoccidioides brasiliensis and treated with Canova Braz. Arch. Biol. Technol. 2006 49 897 903 10.1590/S1516-89132006000700006 133. Sharma K. Arora T. Joshi V. Rathor N. Mehta A. Mehta K. Mediratta P. Substitute of animals in drug research: An approach towards fulfillment of 4R′s Indian J. Pharm. Sci. 2011 73 1 10.4103/0250-474X.89750 22131615 134. Travassos L.R. Silva L.S. Rodrigues E.G. Conti S. Salati A. Magliani W. Polonelli L. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis J. Antim. Chemother. 2004 54 956 958 10.1093/jac/dkh430 135. Thomaz L. García-Rodas R. Guimarães A.J. Taborda C.P. Zaragoza O. Nosanchuk J.D. Galleria mellonella as a model host to study Paracoccidioides lutzii and Histoplasma capsulatum Virulence 2013 4 139 146 10.4161/viru.23047 23302787 136. Scorzoni L. de Paula e Silva A.C.A. Singulani J.L. Leite F.S. de Oliveira H.C. Moraes da Silva R.A. Fusco-Almeida A.M. Mendes-Giannini M.J.S. Comparison of virulence between Paracoccidioides brasiliensis and Paracoccidioides lutzii using Galleria mellonella as a host model Virulence 2015 6 766 776 10.1080/21505594.2015.1085277 26552324 137. Sheehan G. Garvey A. Croke M. Kavanagh K. Innate humoral immune defences in mammals and insects: The same, with differences? Virulence 2018 9 1625 1639 10.1080/21505594.2018.1526531 30257608 138. de Oliveira H.C. Michaloski J.S. da Silva J.F. Scorzoni L. de Paula e Silva A.C.A. Marcos C.M. Assato P.A. Yamazaki D.S. Fusco-Almeida A.M. Giordano R.J. Peptides derived from a phage display library inhibit adhesion and protect the host against infection by Paracoccidioides brasiliensis and Paracoccidioides lutzii Front. Pharmacol. 2016 7 509 10.3389/fphar.2016.00509 28066254 139. Jain K.K. Current Status and Future Prospects of Drug Delivery Systems Drug Delivery System Jain K.K. Methods in Molecular Biology Springer New York, NY, USA 2014 Volume 1141 1 56 978-1-4939-0362-7 140. Cunha-Azevedo E.P. Silva J.R. Martins O.P. Siqueira-Moura M.P. Bocca A.L. Felipe M.S.S. Tedesco A.C. Azevedo R.B. In Vitro antifungal activity and toxicity of itraconazole in DMSA-PLGA nanoparticles J. Nanosci. Nanotech. 2011 11 2308 2314 10.1166/jnn.2011.3576 21449386 141. Brogden R.N. Goa K.L. Coukell A.J. Amphotericin-B Colloidal Dispersion: A review of its use against systemic fungal infections and visceral Leishmaniasis Drugs 1998 56 365 383 10.2165/00003495-199856030-00008 9777313 142. Souza A.C.O. Nascimento A.L. de Vasconcelos N.M. Jerônimo M.S. Siqueira I.M. R-Santos L. Cintra D.O.S. Fuscaldi L.L. Pires Júnior O.R. Titze-de-Almeida R. Activity and in vivo tracking of Amphotericin B loaded PLGA nanoparticles Eur. J. Med. Chem. 2015 95 267 276 10.1016/j.ejmech.2015.03.022 25827397 143. Amaral A.C. Bocca A.L. Ribeiro A.M. Nunes J. Peixoto D.L.G. Simioni A.R. Primo F.L. Lacava Z.G.M. Bentes R. Titze-de-Almeida R. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis J. Antim. Chemother. 2009 63 526 533 10.1093/jac/dkn539 144. Saldanha C.A. Garcia M.P. Iocca D.C. Rebelo L.G. Souza A.C.O. Bocca A.L. Almeida Santos M.F.M. Morais P.C. Azevedo R.B. Antifungal activity of amphotericin b conjugated to nanosized magnetite in the treatment of Paracoccidioidomycosis PLoS Negl. Trop. Dis. 2016 10 e0004754 10.1371/journal.pntd.0004754 27303789 145. Singulani J.L. Scorzoni L. Lourencetti N.M.S. Oliveira L.R. Conçolaro R.S. da Silva P.B. Nazaré A.C. Polaquini C.R. Victorelli F.D. Chorilli M. Potential of the association of dodecyl gallate with nanostructured lipid system as a treatment for paracoccidioidomycosis: In vitro and in vivo efficacy and toxicity Int. J. Pharm. 2018 547 630 636 10.1016/j.ijpharm.2018.06.013 29883792 146. Medina-Alarcón K.P. Singulani J.D.L. Dutra L.A. Pitangui N.D.S. Pereira-da-Silva M.A. dos Santos M.B. Ayusso G.M. Regasini L.O. Soares C.P. Chorilli M. Antifungal activity of 2′-hydroxychalcone loaded in nanoemulsion against Paracoccidioides spp. Future Microbiol. 2020 15 21 33 10.2217/fmb-2019-0095 32043361 147. Medina-Alarcón K.P. Singulani J.L. Voltan A.R. Sardi J.C.O. Petrônio M.S. Santos M.B. Polaquini C.R. Regasini L.O. Bolzani V.S. da Silva D.H.S. Alkyl protocatechuate-loaded nanostructured lipid systems as a treatment strategy for Paracoccidioides brasiliensis and Paracoccidioides lutzii In Vitro Front. Microbiol. 2017 8 1048 10.3389/fmicb.2017.01048 28659880